Peer review

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News

Brid­get Martell on tak­ing Yale spin­out 'to adult­hood'; Cul­li­nan On­col­o­gy CEO an­nounces res­ig­na­tion as Bris­tol My­ers hema­tol­ogy ex­ec is wel­comed aboard

Bridget Martell’s first clinical trial was an unorthodox one.

Then a resident in internal medicine at Yale, she was given an award to explore a career in clinical research — which was how she wound up leading a Phase I study for a therapeutic cocaine vaccine designed to help overcome addiction. She ended up overseeing the trial from Patient 1 to Patient 110 and, in the end, the early trial was positive.

Lu­ba Green­wood takes the helm at Ko­jin Ther­a­peu­tics, steer­ing an all-fe­male C-suite; Alex­ion R&D chief packs up for change of scenery at VC firm

How rare is it to find a woman leading a micro- or small-cap biotech company? According to a recent survey, it happens less than 6% of the time. And all-female C-suites? Almost unheard of.

But on Thursday, Kojin Therapeutics officially tapped Luba Greenwood as its first CEO, completing an all-female C-suite. All of the biotech’s senior scientists are women too, as is the scientific co-founder. It’s a moment that Greenwood always believed would come.

Flag­ship turns to No­var­tis HR gu­ru in lat­est ad­di­tion; David Grainger sad­dles up to new po­si­tion at Centes­sa while Pfiz­er's Rod MacKen­zie pre­pares to ride in­to the sun­set

→ In a development that just seemed to add up neatly given Medicxi’s involvement with Centessa, the brainchild of Francesco de Rubertis has named fellow Medicxi co-founder David Grainger as chief innovation officer. Diving in here at Centessa means that Grainger will cede his previous Medicxi responsibilities but he will “continue in a consulting capacity,” as confirmed by our Amber Tong on Tuesday.

Sporos Bioven­tures taps first CEO dur­ing pe­ri­od of 'ex­plo­sive growth'; In the wake of murky Hunter syn­drome da­ta, De­nali bulks up C-suite

Almost five months after emerging from stealth mode on a mission to leverage work being done in “flyover” states like Texas and Wisconsin, Sporos Bioventures has named its first official CEO.

Amit Rakhit left his role as president and CMO of Ovid Therapeutics to take the helm at Sporos, a Houston-based upstart launched by Genzyme vet Michael Wyzga, ex-MD Anderson chief Ron DePinho, BridgeBio co-founder Peter Feinberg, Tvardi Therapeutics CSO Jeno Gyuris, and entrepreneur Alex Cranberg.

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March to buy its T cell collaborator and integrate the staff into the R&D unit. Scibetta has signed on as CEO of antibody startup ImmuneID, co-founded and chaired by Longwood Fund’s Christoph Westphal with tech coming from Stephen Elledge’s lab at Harvard. So ends a fleeting CEO tenure for David Donabedian, who will stay close by as an advisor. Scibetta, the CFO and later president of Pacira Pharmaceuticals until he joined Maverick in 2017, steps forward to lead a biotech that’s chalked up $70 million in financing, including $50 million in a Series A this summer.

A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es Eli Lil­ly alum as CFO

→ Last week we told you about the CMO revolving door at ADC Therapeutics, as Joseph Camardo replaced the departing Jay Feingold. The next opportunity for Feingold in the CMO slot has opened up at antibody-drug conjugate and mAb developer Pyxis Oncology, which has added several new execs and scientific advisory board members in recent months, including ex-Immunovant CFO Pamela Yanchik Connealy. Before his tenure at ADC, Feingold was Daiichi Sankyo’s VP of US medical affairs and chairman of the Global Medical Affairs Oversight Committee. Within weeks in March, Pyxis struck a licensing deal with Pfizer for two of its ADCs and raked in $152 million from a Series B round.

Flag­ship keeps ex-FDA com­mish Stephen Hahn busy with an­oth­er CMO gig; Daphne Koller makes key hire at in­sitro by wel­com­ing Google and Face­book vet

→ What’s next for Stephen Hahn, you ask? It’s an interim CMO post at Flagship’s YourBio Health, the maker of kits that sidestep the conventional methods of blood collection in favor of push-button devices. Hahn joined Flagship in June as CMO of its Preemptive Medicine and Health Security initiative after a topsy-turvy run as FDA commissioner in the Trump administration. Hahn received his share of flak when he extolled the virtues of convalescent pharma before the emergency use authorizations of the Moderna and Pfizer/BioNTech Covid-19 vaccines, eventually walking back his comments. Conversely, Hahn received kudos for staying resolute on safety followup from clinical trials. A month after his FDA tenure, Hahn joined the board of directors at Blackfynn.

Zio­pharm finds new CEO af­ter six-month search; CFO tran­si­tion at Lon­za to take place in De­cem­ber

Less than a year removed from a successful activist attack, Ziopharm Oncology appointed a new CEO this week. Taking the reins will be Kevin Boyle, who comes over after leading Kuur Therapeutics to a $185 million buyout back in May.

It’s been a tough few years for Ziopharm, which in addition to taking on the withering activist attack saw significant turnover at the C-suite level, culminating in longtime CEO Laurence Cooper hitting the exit in February. That kicked off a nearly half-year search that has now found Boyle set to take charge.

As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

The biggest bright spot for AstraZeneca over the last few years has been its work in oncology, as CEO Pascal Soriot has helped shepherd blockbusters Imfinzi, Lynparza, and Calquence, among other cancer medicines.

One of the top executives from the cancer division is now making the leap to the larger C-suite. The Swedish-British pharma named its oncology chief development officer Cristian Massacesi as the new CMO.

No­vavax grabs an­oth­er CFO while Pat Cotro­neo re­tires from Fi­bro­Gen; Eli Lil­ly re­assem­bles key staff af­ter bio­med­i­cines unit split

→ The perennial Charlie Brown of vaccine development, Novavax is grappling with Lucy’s knack for pulling the football away once again, this time with its Covid-19 vaccine as the FDA pushed back another bid for an EUA earlier this month. In the meantime, Novavax has found Jim Kelly to replace Greg Covino as CFO, leaving John Trizzino one less C-suite title to juggle. Kelly, the ex-CFO at Vanda Pharmaceuticals, was just in this space in October 2020 when he succeeded Greg Patrick as CFO of Supernus, and now he makes a quick change to a biotech that can’t seem to avoid taking on Sisyphean qualities no matter what it does.